Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$12.46 - $29.95 $19.3 Million - $46.4 Million
1,550,533 Added 7.65%
21,824,392 $647 Million
Q3 2023

Nov 13, 2023

SELL
$14.09 - $19.87 $8.89 Million - $12.5 Million
-631,127 Reduced 3.02%
20,273,859 $322 Million
Q2 2023

Aug 11, 2023

BUY
$3.75 - $20.05 $10.9 Million - $58.3 Million
2,908,657 Added 16.16%
20,904,986 $394 Million
Q1 2023

May 12, 2023

SELL
$3.67 - $4.92 $72,199 - $96,791
-19,673 Reduced 0.11%
17,996,329 $69.1 Million
Q4 2022

Feb 13, 2023

BUY
$4.55 - $6.31 $2.6 Million - $3.6 Million
570,976 Added 3.27%
18,016,002 $89.4 Million
Q3 2022

Nov 14, 2022

SELL
$4.48 - $6.47 $1.94 Million - $2.8 Million
-432,243 Reduced 2.42%
17,445,026 $83.4 Million
Q2 2022

Aug 12, 2022

BUY
$3.15 - $5.76 $4.55 Million - $8.32 Million
1,444,336 Added 8.79%
17,877,269 $80.4 Million
Q1 2022

May 12, 2022

BUY
$4.26 - $7.48 $6.69 Million - $11.7 Million
1,569,629 Added 10.56%
16,432,933 $78.2 Million
Q4 2021

Feb 10, 2022

SELL
$4.75 - $7.5 $2.46 Million - $3.89 Million
-518,571 Reduced 3.37%
14,863,304 $110 Million
Q3 2021

Nov 09, 2021

SELL
$5.02 - $6.59 $173,546 - $227,822
-34,571 Reduced 0.22%
15,381,875 $87.2 Million
Q2 2021

Aug 11, 2021

BUY
$5.79 - $8.6 $89.3 Million - $133 Million
15,416,446 New
15,416,446 $102 Million

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.